Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01789736 · ClinicalTrials.gov registry record · Phase 2
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Phase 2 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 234
- Enrollment target
NCT01789736 is a Phase 2 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 234 participants.
The verdict
NCT01789736, a Phase 2 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 234 participants
- Enrollment target
Study Summary
In the double-masked, randomized, multi-center, active-controlled parallel study, patients will be randomized to receive either a fixed dose combination of AR-12286 and travoprost, AR-12286, or travoprost. The hypothesis is that there is no difference between each treatment arm.
Interventions
- DRUG PG286 Ophthalmic Solution 0.5%
- DRUG AR-12286 Ophthalmic Solution 0.5%
- DRUG Travoprost Ophthalmic Solution 0.004%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01789736
The ClinicalTrials.gov registry entry for NCT01789736 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PG286 Ophthalmic Solution 0.5% is the first listed.
NCT01789736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01789736 about?
NCT01789736 is a clinical study titled "A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days". In the double-masked, randomized, multi-center, active-controlled parallel study, patients will be randomized to receive either a fixed dose combination of AR-12286 and travoprost, AR-12286, or travoprost. The hypothesis is that there is no difference between each treatment arm.
What is the current status of trial NCT01789736?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2013-02. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01789736?
The interventions under investigation include: PG286 Ophthalmic Solution 0.5% (DRUG), AR-12286 Ophthalmic Solution 0.5% (DRUG), Travoprost Ophthalmic Solution 0.004% (DRUG).
Who is sponsoring clinical trial NCT01789736?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.